Updates are available Erratum dated 2018-04-01

Article History

First Online: 9 March 2018

Change Date: 27 March 2018

Change Type: Erratum

Change Details: In the version of this article originally published online, the heading of the third column in Table 1 was "Percentage of lesions that meet criteria". This heading should be "Percentage of patients that meet criteria". The error has been corrected in the print and online versions.

Competing interests

: M.H., G.C.D. and F.F. declare no competing interests. R.G. has received support for scientific meetings and courses and honoraria for advisory work from Bayer, Biogen, Merck, Novartis. O.C. serves as a consultant for Biogen, Novartis and General Electric, for which honoraria are all paid to the University College London Institute of Neurology. F.B. serves as a consultant for Biogen, Bayer, Genzyme, Jansen Research, Merck, Novartis, Roche, Synthon BV and Teva. N.D.S. has received honoraria from Biogen, Genzyme, Merck, Novartis, Schering and Teva for consulting services, speaking and travel support. He serves on advisory boards for Biogen, Merck and Novartis. C.E. has received funding for travel and speaker honoraria from Biogen, Bayer, Genzyme, Merck, Novartis, Shire and Teva, funding for research from Biogen, Merck and Teva, and has served on scientific advisory boards for Bayer, Biogen, Merck, Novartis, Roche and Teva. M.F. serves on a scientific advisory board for Teva, has received compensation for consulting services and/or speaking activities from Biogen, Merck, Novartis and Teva, and has received research support from Biogen, Novartis and Teva. F.P. has served on scientific advisory boards for MedImmune and the Novartis OCTIMS study, has received travel funding and/or speaker honoraria from Alexion-Chugai, Bayer, Biogen, MedImmune, Merck, Novartis, Sanofi, Shire Pharmaceuticals and Teva, has consulted for Alexion, Biogen, MedImmune, Sanofi and Shire Pharmaceuticals, and has received research support from Alexion, Bayer, Biogen, Merck, Novartis, Sanofi and Teva. P.P. has received speaker honoraria from Biogen, EXCEMED and Novartis. A.R. serves on scientific advisory boards for Novartis, OLEA Medical and Sanofi, has received speaker honoraria from Bayer, Biogen, Bracco, Merck, Novartis, Roche, Sanofi and Teva, and has research agreements with Siemens AG. L.K.'s institute (University Hospital Basel, Switzerland) has received, and used exclusively for research support, steering committee, advisory board and consultancy fees from Actelion, Addex, Bayer, Biogen, Biotica, Genzyme, Eli-Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi, Santhera, Siemens, Teva, UCB and XenoPort, speaker fees from Bayer, Biogen, Merck, Novartis, Sanofi and Teva, support of educational activities from Bayer, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi and Teva, royalties from Neurostatus, and grants from Bayer Healthcare, Biogen, Merck, Novartis, Roche and Roche Research Foundations.T.Y. has received consultant, clinical trial or travel fees from Biogen, the European Society of Radiology, GlaxoSmithKline, IXICO, Novartis and Merck. J.F. has served on scientific advisory boards for, and received funding of travel for participation in scientific advisory boards and honoraria from, Biogen, Genzyme, Merck, Novartis, Sanofi, Takeda and Teva. C.G. has received compensation for consulting from Bayer and Biogen, and speaker fees for lectures from Biogen, Bayer, Genzyme, Merck, Novartis and Teva. C.G. has received speaker fees from Bayer, Biogen, Genzyme, Merck and Teva. J.S.-G. has received compensation for serving on scientific advisory boards or on speaker bureaus from Biogen, Merck, Novartis, Sanofi and Teva. N.E. has received honoraria from Biogen, Genzyme and Novartis for consulting services, speaking and travel support. He serves on advisory boards for Biogen, Merck and Novartis. J.P. has received support for scientific meetings and honoraria for advisory work from ABIDE, Alexion, Biogen, Bayer, Chugai Pharma, MedImmune, Merck, Novartis, Roche and Teva, and unrestricted grants from Bayer, Biogen, Merck and Novartis.